EUVIMEDEUVIMED entdecken
Crossref

Identification of novel gene expression patterns and pathways involved in PARP-1 inhibitor resistance

Zulfa Khan, Anish Gomatam, Upadhyayula Suryanarayana Murty, Vaibhav A Dixit

Mammalian Genome · 2025

DOI: 10.1007/s00335-025-10134-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mammalian Genome, 2025. Verfasst von Zulfa Khan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, (NIPER Guwahati), Department of Pharmaceuticals, Mini…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Poly(ADP-ribose) Polymerase Inhibitors, Ovarian Neoplasms, Poly (ADP-Ribose) Polymerase-1. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Ministry of Electronics and Information technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

US-FDA has approved PARP-1 inhibitors (Talazoparib, Olaparib, Rucaparib, and Niraparib) as the first line of treatment for many cancer types (e.g., breast, ovarian, pancreatic, and prostate) caused by mutations in breast cancer gene 1 and 2 (BRCA1/2). However, developing resistance to PARP-1 inhibitors is a major concern, which limits therapeutic effectiveness. In the present study, we identified novel gene signatures implicated in developing resistance to Olaparib. Meta-analysis was performed on publicly available RNA-Seq data related to ovarian and breast cancers from the GEO (Gene Expression Omnibus) database. Differential gene expression analysis, gene ontology, KEGG pathway enrichment, and protein-protein interaction (PPI) networking analyses were performed. A total of 139 Common DEGs (Differentially Expressed Genes) were identified, comprising 69 and 70 genes that were upregulated and downregulated respectively. KEGG Pathways "P53 signaling pathway" and "Positive regulation of developmental process(BP)", "endoplasmic reticulum lumen(CC)," and "growth factor binding(MF)", were found to be potentially associated with Olaparib resistance. Five hub genes were identified using PPI networking of which FN1, CCN2, and JUN may play a significant role in the development of Olaparib resistance and could be promising therapeutic and diagnostic biomarkers for dealing with Olaparib resistance in BRCA1/2 mutant breast and ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmPoly(ADP-ribose) Polymerase InhibitorsOvarian NeoplasmsPoly (ADP-Ribose) Polymerase-1Breast NeoplasmsHumansPiperazinesPhthalazinesGene Expression Regulation, NeoplasticFemaleSignal TransductionGene Expression ProfilingProtein Interaction MapsGene Regulatory NetworksBRCA1 ProteinTranscriptome

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsPiperazinesPhthalazinesolaparibPoly (ADP-Ribose) Polymerase-1PARP1 protein, humanBRCA1 Protein

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, (NIPER Guwahati), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India, Sila Katamur (Halug…

Förderung

  • Ministry of Electronics and Information technology

Zitieren

APA

Khan, Z., Gomatam, A., Murty, U. S., & Dixit, V. A. (2025). Identification of novel gene expression patterns and pathways involved in PARP-1 inhibitor resistance. Mammalian Genome. https://doi.org/10.1007/s00335-025-10134-y

Vancouver

Khan Z, Gomatam A, Murty US, Dixit VA. Identification of novel gene expression patterns and pathways involved in PARP-1 inhibitor resistance. Mammalian Genome. 2025. doi:10.1007/s00335-025-10134-y

BibTeX
@article{Khan2025,
  author = {Khan, Zulfa and Gomatam, Anish and Murty, Upadhyayula Suryanarayana and Dixit, Vaibhav A},
  title = {Identification of novel gene expression patterns and pathways involved in PARP-1 inhibitor resistance},
  journal = {Mammalian Genome},
  year = {2025},
  doi = {10.1007/s00335-025-10134-y}
}
Kostenlos starten →